CHOP-E Treatment Indication
CHOP-E (cyclophosphamide, doxorubicin, vincristine, prednisone, etoposide), also known as CHOEP, is primarily used as first-line chemotherapy for peripheral T-cell lymphomas (PTCLs), including anaplastic large cell lymphoma (ALCL) and other aggressive T-cell histologies. 1
Primary Indications
Peripheral T-Cell Lymphomas (Preferred Use)
CHOEP is listed as a preferred first-line regimen for most PTCL histologies according to current NCCN guidelines 1. This includes:
- ALCL (ALK-positive and ALK-negative): Listed as an "other recommended regimen" after brentuximab vedotin + CHP
- PTCL-NOS (peripheral T-cell lymphoma, not otherwise specified)
- AITL (angioimmunoblastic T-cell lymphoma)
- Other CD30-positive T-cell histologies
The rationale for CHOEP in PTCLs stems from the poor outcomes historically seen with standard CHOP alone in these aggressive T-cell malignancies. The addition of etoposide aims to intensify therapy and improve disease control 1, 2.
Age-Specific Considerations
For patients ≤60 years old, CHOEP is well-tolerated and feasible with acceptable toxicity 3. The regimen can be delivered at full doses with excellent adherence (median relative dose ≥98%) in this younger population.
For patients >60 years old, CHOEP requires caution due to significantly increased toxicity 4, 3. In elderly patients, CHOEP is associated with:
- Marked dose erosion (up to 27% of patients receiving <80% of planned dose with CHOEP-14)
- Higher infection rates
- Increased transfusion requirements
- Longer hospitalizations
- More antibiotic use
Despite these concerns, CHOEP-21 (3-weekly schedule) showed improved outcomes compared to CHOP-21 in elderly patients, with 5-year event-free survival of 43.8% versus 32.5% 4.
Dosing Schedules
Two main schedules exist:
CHOEP-21 (3-weekly):
- Cyclophosphamide 750 mg/m²
- Doxorubicin 50 mg/m²
- Vincristine 1.4 mg/m² (or 2 mg flat dose)
- Etoposide 100 mg/m² days 1-3
- Prednisone 100 mg days 1-5
- Repeated every 21 days
CHOEP-14 (2-weekly with G-CSF):
- Same doses but repeated every 14 days
- Requires G-CSF support starting day 4
Alternative Uses (Less Common)
Hodgkin Lymphoma
CHOPE (slightly different formulation) has been evaluated in advanced-stage Hodgkin disease with 92% overall response rate after 4 cycles, though this is not a standard indication 5.
Aggressive B-Cell Lymphomas
While CHOP forms the backbone of B-cell lymphoma treatment, the addition of etoposide (CHOEP) is NOT standard for B-cell lymphomas where rituximab-CHOP remains the gold standard 6, 7. The evidence does not support routine etoposide addition in diffuse large B-cell lymphoma.
Key Clinical Pitfalls
Do not use CHOEP as first-line for ALCL without considering brentuximab vedotin + CHP first, which has superior outcomes (5-year OS 69% vs 60% for CHOP, with likely similar or better results than CHOEP) 1
Monitor for cardiotoxicity carefully - the anthracycline component causes cumulative cardiac dysfunction, with significant LVEF reduction and elevated cardiac biomarkers at cumulative doxorubicin doses ≥250 mg/m² 8
Expect severe myelosuppression - grade 4 neutropenia occurs in 53-90% of patients depending on schedule, with febrile neutropenia in 11-15% 3
In elderly patients (>60 years), strongly consider CHOP-14 over CHOEP due to better toxicity profile while maintaining efficacy 4